ABSTRACT
Delivery of small interfering RNA (siRNA) to suppress glioblastoma growth is a hurdle due to the critical obstacles of the blood-brain barrier and the siRNA properties of such as high negative charges and instability in serum. Therefore, the passage of siRNA to targeted cells is limited. Several siRNA carriers have been constructed using cell-penetrating peptides (CPPs) since the CPPs have shown a high potential for oligonucleotide delivery into the cells. In this study, two CPPs, PepFect 14 (PF14) and the amphipathic peptide PepFect 28 (PF28), were modified with targeting peptides by covalent conjugation and non-covalent complex formation to improve glioma-targeted specificity and gene-silencing efficiency. In conclusion, we have established an efficient non-covalently complexed carrier (PF14:TG1) for siRNA delivery to human glioblastoma cells (U87), showing a significant two-fold increase in gene-silencing efficiency compared to the parent peptide PF14 and also improved specificity to U87 cells compared to non-glioma targeted cells.
Subject(s)
Cell-Penetrating Peptides/administration & dosage , Glioblastoma/metabolism , RNA, Small Interfering/administration & dosage , Cell Line, Tumor , Cell Proliferation/genetics , Cell Proliferation/physiology , Cell-Penetrating Peptides/chemistry , Dynamic Light Scattering , Gene Silencing/physiology , Humans , RNA, Small Interfering/chemistryABSTRACT
Receptor-mediated transcytosis remains a major route for drug delivery across the blood-brain barrier (BBB). PepFect 32 (PF32), a peptide-based vector modified with targeting ligand (Angiopep-2) binding to low-density lipoprotein receptor-related protein-1 (LRP-1), was previously found to be a promising vector for plasmid delivery across an in vitro model of the BBB. Cellular uptake of PF32/plasmid DNA (pDNA) complexes was speculated the internalization via LRP-1 receptor. In this study, we prove that PF32/pDNA nanocomplexes are not only transported into brain endothelial cells via LRP-1 receptor-mediated endocytosis, but also via scavenger receptor class A and B (SCARA3, SCARA5, and SR-BI)-mediated endocytosis. SCARA3, SCARA5, and SR-BI are found to be expressed in the brain endothelial cells. Inhibition of these receptors leads to a reduction of the transfection. In conclusion, this study shows that scavenger receptors also play an essential role in the cellular uptake of the PF32/pDNA nanocomplexes.
Subject(s)
Blood-Brain Barrier/metabolism , DNA/administration & dosage , Peptides/administration & dosage , Receptors, Scavenger/metabolism , Animals , Cell Line , DNA/chemistry , Mice , Peptides/chemistry , PlasmidsABSTRACT
Cell-penetrating peptides provide a promising strategy for delivery of drugs across the blood-brain barrier. Here, we present an overview of CPP and peptide-mediated delivery to the central nervous system as well as a Transwell in vitro model to evaluate passage across an endothelial cell layer mimic of the blood-brain barrier.
Subject(s)
Blood-Brain Barrier/metabolism , Cell-Penetrating Peptides/metabolism , DNA/administration & dosage , Plasmids/administration & dosage , Animals , Cell Culture Techniques/instrumentation , Cell Culture Techniques/methods , Cell-Penetrating Peptides/chemistry , DNA/chemistry , DNA/genetics , Equipment Design , Gene Transfer Techniques , Glioma/metabolism , Humans , Luciferases/analysis , Luciferases/genetics , Luminescent Measurements/methods , Plasmids/chemistry , Plasmids/geneticsABSTRACT
Cell-penetrating peptides (CPPs) have been used as vehicles to deliver various cargos into cells and are promising as tools to deliver therapeutic biomolecules such as oligonucleotides both in vitro and in vivo. CPPs are positively charged and it is believed that CPPs deliver their cargo in a receptor-independent manner by interacting with the negatively charged plasma membrane and thereby inducing endocytosis. In this study we examine the mechanism of uptake of several different, well known, CPPs that form complexes with oligonucleotides. We show that these CPP:oligonucleotide complexes are negatively charged in transfection-media and their uptake is mediated by class A scavenger receptors (SCARA). These receptors are known to promiscuously bind to, and mediate uptake of poly-anionic macromolecules. Uptake of CPP:oligonucleotide complexes was abolished using pharmacological SCARA inhibitors as well as siRNA-mediated knockdown of SCARA. Additionally, uptake of CPP:oligonucleotide was significantly increased by transiently overexpressing SCARA. Furthermore, SCARA inhibitors also blocked internalization of cationic polymer:oligonucleotide complexes. Our results demonstrate that the previous held belief that CPPs act receptor independently does not hold true for CPP:oligonucleotide complexes, as scavenger receptor class A (SCARA) mediates the uptake of all the examined CPP:oligonucleotide complexes in this study.
Subject(s)
Cell-Penetrating Peptides/metabolism , Oligonucleotides/administration & dosage , Plasmids/administration & dosage , Polymers/metabolism , Scavenger Receptors, Class A/metabolism , Cell Line , Endocytosis , HeLa Cells , Humans , RNA, Small Interfering/genetics , Scavenger Receptors, Class A/antagonists & inhibitors , Scavenger Receptors, Class A/genetics , TransfectionABSTRACT
A series of novel, amphipathic cell-penetrating peptides was developed based on a combination of the model amphipathic peptide sequence and modifications based on the strategies developed for PepFect and NickFect peptides. The aim was to study the role of amphipathicity for peptide uptake and to investigate if the modifications developed for PepFect peptides could be used to improve the uptake of another class of cell-penetrating peptides. The peptides were synthesized by solid phase peptide synthesis and characterized by circular dichroism spectroscopy. Non-covalent peptide-plasmid complexes were formed by co-incubation of the peptides and plasmids in water solution. The complexes were characterized by dynamic light scattering and cellular uptake of the complexes was studied in a luciferase-based plasmid transfection assay. A quantitative structure-activity relationship (QSAR) model of cellular uptake was developed using descriptors including hydrogen bonding, peptide charge and positions of nitrogen atoms. The peptides were found to be non-toxic and could efficiently transfect cells with plasmid DNA. Cellular uptake data was correlated to QSAR predictions and the predicted biological effects obtained from the model correlated well with experimental data. The QSAR model could improve the understanding of structural requirements for cell penetration, or could potentially be used to predict more efficient cell-penetrating peptides.
Subject(s)
Cell-Penetrating Peptides/chemistry , Cell-Penetrating Peptides/metabolism , Drug Design , Amino Acid Sequence , Cell Membrane Permeability/drug effects , Cell Membrane Permeability/physiology , Cell-Penetrating Peptides/genetics , HEK293 Cells , Humans , Molecular Sequence Data , Quantitative Structure-Activity RelationshipABSTRACT
Cell-penetrating peptides provide a highly promising strategy for intracellular drug delivery. One relevant clinical application of cell-penetrating peptides is cancer therapeutics. Peptide based delivery could increase the uptake of drugs in tumor cells and thereby increase the efficacy of the treatment, either of conventional small molecular drugs or oligonucleotide based therapeutics. This review is focused on the cancer applications of cell penetrating peptides as delivery systems; different aspects of drug loading, cargoes and delivery are discussed together with methods for targeted delivery, activatable cell-penetrating peptides and transducible agents coupled to cell-penetrating peptides.
